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ABSTRACT
Objectives: We aimed to study whether patient-
reported outcomes, measured by quality of life (QoL)
and functional class, are sensitive to pleural effusion
(PLE) in patients with heart failure (HF), and to study
changes in QoL and functional class during follow-up
of PLE.
Methods: A cohort of 62 patients from an outpatient
HF clinic was included. The amount of PLE was
quantified using a pocket-sized ultrasound imaging
device. Self-reports of QoL and functional class were
collected using the Minnesota Living with Heart Failure
Questionnaire (MLHFQ) and the New York Heart
Association (NYHA) functional classification.
Results: At baseline, 26 (42%) patients had PLE of
which 19 (31%) patients had moderate to severe
amounts of PLE. Patients with no to mild PLE had a
lower MLHFQ score (mean 42, SD 21) compared with
patients with a moderate to severe amount of PLE
(mean 55, SD 24), p=0.03. For 28 patients (45%) with
follow-up data, we observed a linear improvement of
the MLHFQ-score (3.2, 95% CI 1.2 to 5.1) with each
centimetre reduction of PLE. Correspondingly, patient-
reported NYHA-class followed the same pattern as the
MLHFQ-score.
Conclusions: Our study indicates that patient-reported
outcome measures as MLHFQ may be sensitive tools
to identify patients with HF at highest risk of
symptomatic PLE and that treatment targeting
reduction of PLE during follow-up is essential to
improvement of QoL and functional capacity of
outpatients with HF.
Trial registration number: NCT01794715; Results
INTRODUCTION
Pleural effusion (PLE) is a common sign
associated with congestion and worsening of
heart failure (HF)1 and is often followed by
dyspnoea.2 However, the degree of dyspnoea
may not correlate with the amount of PLE3 4
and screening for PLE is often restricted to
patients with HF with clinical signs of PLE.
It is well known that patients with HF experi-
ence significant reductions in quality of life
(QoL).5 6 Thus, initiatives to find treatment
strategies that improve QoL have become an
important objective in the follow-up of patients
with HF.7 In cancer care, initiatives to reduce
PLE seem to be an essential palliative step,
which has proven to improve QoL and
decrease symptom burden without particular
side effects.8 9 However, poor self-reported
QoL or functional capacity are not convention-
ally used indicators for screening and treat-
ment of PLE in patients with HF. This may be
due to the fact that it is largely unknown if
QoL or functional class is associated with the
presence of PLE in patients with HF. Further,
to the best of our knowledge, no previous
studies have investigated whether QoL and
functional class improves in patients with HF
when PLE is successfully treated. Thus, we
aimed to study whether patient-reported out-
comes (QoL and functional class) are sensitive
to PLE, and to study changes in QoL and func-
tional class during follow-up of PLE.
Strengths and limitations of this study
▪ Patient-reported outcome measures of quality of
life (QoL) and objective measurements of pleural
effusion (PLE) by point-of-care ultrasound was
followed up repeatedly in a heart failure (HF) out-
patient clinic.
▪ QoL is increasingly emphasised in treatment
strategies and point-of-care ultrasound is
recently recommended as a tool to identify PLE
in European Society of Cardiology guidelines.
▪ The study was conducted at one single HF out-
patient clinic and the sample size was small.
However, the presented population is previously
shown to be comparable with studies from other HF
clinics with regard to HF severity, age, sex,
New York Heart Association class and comorbidity.
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METHODS
Study population and design
This was a prospective follow-up study with inclusion of
62 patients admitted to the outpatient HF clinic at the
non-university Levanger Hospital, Norway between 15
April and 21 June 2013.10 11 The sample size was deter-
mined in order to validate the feasibility and reliability
of point-of-care ultrasound examination.10 11 The HF
diagnosis was confirmed according to the European
Society of Cardiology (ESC) guidelines by clinical exam-
ination,12 medical history and echocardiographic exam-
ination by one of four experienced cardiologists.10 11
All patients provided their written informed consent
to participate. The exclusion criteria were inability or
unwillingness to consent or HF worsening requiring hos-
pital admission at entry. The study observed patient-
reported QoL in the follow-up of a clinical trial regard-
ing feasibility and reliability of point-of-care ultrasound
in order to determine PLE (ClinicalTrials.gov: ID:
NCT01794715). Data regarding feasibility and influence
of point-of-care ultrasound have been recently pub-
lished.10 11 The observational part of the study was con-
ducted according to the Second Declaration of Helsinki.
Follow-up
The follow-up of patients at the outpatient HF clinic was
managed by two nurses specialised in cardiovascular and
intensive care, working in close cooperation with four
cardiologists. Briefly, the visits included patient educa-
tion, self-management counselling and optimisation of
the treatment for HF according to the 2012 ESC HF
guidelines12 in order to reduce the amount of PLE and
improve the functional capacity, QoL and prognosis of
the patients. None of the patients with HF needed thera-
peutic drainage of PLE. The follow-up schedule of the
outpatient HF clinic was individualised depending on
the condition of the patients. The number of visits
ranged from one to four visits during the study period.
The final follow-up was defined as the visit when the
condition of the patient was satisfactory and stable.
Twenty-eight (45%) patients had a final follow-up visit in
the study period (figure 1).
Measurements
Measurement of PLE
The nurses received a short, but dedicated training pro-
gramme in focused point-of-care ultrasound examina-
tions of the pleural cavities. The high feasibility and
excellent reliability for quantification of PLE by
point-of-care ultrasound performed by the nurses are
comprehensively described in a recent publication.10
Ultrasound examinations were performed using the
Vscan (GE Ultrasound, Horten, Norway) at each visit.
With the transducer placed in the intercostal space, the
liver and spleen were used as reference points to identify
the diaphragm of the right and left hemithoraces,
respectively. During quiet breathing, the posterior chest
was scanned along the paravertebral, scapular, posterior
and medial axillary lines, continuously focusing on the
diaphragm as a reference point. PLE was assessed in the
costodiaphragmatic angle by assessing the dimension
between the diaphragm and the lung surface (measured
in the middle between the transducer and the mediasti-
num). The amount of PLE was categorised in four
groups as (1) no PLE, (2) insignificant when present in
the costodiaphragmatic angle only, (3) small to moder-
ate when the measurement as described above was
<3 cm and (4) significant when the measurement was ≥
3 cm. We also dichotomised the PLE measures as no to
mild (groups (1) and (2)) and moderate to severe
(groups (3) and (4)).
Patient-reported outcome measures
The patients completed the questionnaires before the
clinical examination at the baseline visit and at the final
follow-up visit as recommended for patient-reported
outcomes.13
The functional class was self-reported according to the
New York Heart Association (NYHA) classification14 on
the validated Norwegian version of this instrument.15
QoL was reported by the validated Minnesota Living
with Heart Failure Questionnaire (MLHFQ), which
quantifies how patients with HF perceive their own QoL
associated with the HF symptoms and treatment the pre-
ceding month. The questionnaire consists of 21 items
where the patients are asked to rate how each item pre-
vents them from living the life they desire using a six-
point Likert scale from 0 to 5 (0= not at all, 5= all the
time). The MLHFQ items include: physical HF symp-
toms (dyspnoea, fatigue, peripheral oedema and sleep-
ing difficulties); psychological HF symptoms (anxiety
and depression) and social/functional impairment due
Figure 1 Shows the flow chart of study recruitment and
follow-up. The follow-up schedule of the outpatient HF clinic
was individualised depending on the condition of the patients.
The number of visits ranged from one to four visits during the
study period. The final follow-up was defined as the visit when
the condition of the patient was satisfactory and stable.
Twenty-eight (45%) patients had a final follow-up visit in the
study period. HF, heart failure.
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to HF (walking, climbing stairs, work, household or
labour, need to rest, going places away from home,
doing things with family and friends, eating, concentra-
tion, memory, loss of self-control, being a burden to
others and sexual activity). The total score range from 0
to105, where the higher the score, the poorer the QoL.
A reduction of 5 units or more in the MLHFQ-score by
treatment is considered as clinically meaningful.16 We
defined a MLHFQ-score >40 to be an indicator for poor
QoL as this cut-off includes the patients that scores in
the upper quartile of the moderate QoL category.17
Clinical examination, blood tests and medications
The specialised nurses examined the patients at all visits.
The clinical examinations included ECG (sinus rhythm or
not), measurement of the blood pressure (mmHg), heart
rate (beats/min) and weight (to nearest 0.5 kg).10 11
Blood samples were collected at each visit and analysed
at the hospital’s International Electrotechnical Commision
(IEC) 17025-accredited laboratory. Creatinine was analysed
by an enzymatic method developed by Abbott and
N-terminal pro-brain natriuretic peptide (NT-proBNP) by
electrochemiluminescence immunoassay (ECLIA).
Estimated glomerulus filtration rate (e-GFR) was calcu-
lated by the chronic kidney disease epidemiology collabor-
ation (CKD-EPI) formula.18
The use of β-blockers was coded as 0 (no use) or 1 (use
of) and the same coding was applied for the prescription
of ACE inhibitors and angiotensin receptor blockers
(ARBs). For diuretics, we recalculated the doses of
furosemide, hydrochlorthiazide and bendrofumethiazide
to equivalent doses of bumetanide. In the analyses,
40 mg furosemide, 12.5 mg hydrochlorthiazide and
2.5 mg bendrofumethiazide were each recalculated to
1 mg bumetanide.11
Statistical analysis
Comparisons of the baseline characteristics between the
participants with no to mild PLE and the participants
with moderate to severe PLE and between those partici-
pants that self-reported a MLHFQ-score ≤40 compared
with those who scored higher were performed by t-test
for continuous variables and χ2-test for categorical data.
One-way analyses of variance were used in order to
assess the differences between MLHFQ-scores in the dif-
ferent categories of PLE and NYHA-classes. For analyses
of trend, we treated the PLE categories and NYHA-class
as continuous variables in a logistic regression model.
Pearson correlation was used to investigate the correl-
ation between patient-reported NYHA-class and
MLHFQ-score. Sensitivity, specificity, positive predictive
and negative predictive values of the MLHFQ cut-off to
detect PLE were calculated at baseline.
Generalised estimating equation with robust SEs and
exchangeable correlation structure and inbuilt correction
for age was used to model the change of the
MLHFQ-score associated with change of PLE over time.
For NYHA-class, we used the log link function of
generalised estimating equation. In our second model, we
adjusted for sex. In the third to seventh model, we added
potential confounders (β-blockers, bumetanide-equivalent
diuretic doses and ACE inhibitors/ARBs, change in
weight and change of systolic blood pressure). These vari-
ables were added one by one to model 1, as the sample
size was limited. We used a two-way graph based on linear
regression to model the change in MLHFQ-score by
change in centimetre (cm) PLE. We investigated the
potential effect modification by sex and defined the crit-
ical p value to be <0.10 for the interaction term. For all
other analyses we considered p <0.05 as significant.
Statistical analyses were performed in Stata SE/13.1 for
windows (© Stata Corp LP, Collage Station, Texas, USA).
RESULTS
Table 1 shows the baseline characteristics of the patients
(n=62) by PLE amount at baseline. As expected, the
group with no or mild PLE had lower NT-proBNP at base-
line than the group with moderate to severe PLE. There
was a higher proportion of patients with sinus rhythm
(49%) in the group with no to mild PLE compared with
the group with moderate to severe PLE (21%). However,
the two groups were comparable in age, sex, blood pres-
sure, heart rate and the use of HF medication (all p>0.1).
Self-reported MLHFQ-score >40 at baseline was asso-
ciated with higher NYHA-class compared with
MLHFQ-score ≤40 (p<0.001) (data not shown).
As shown in figure 2, the patient-reported
MLHFQ-score at baseline depended on the PLE quan-
tity (p=0.02). Approximately half of the patients with no
PLE and most patients with moderate-to severe PLE had
a MLHFQ-score >40. The mean MLHFQ-score in the
patients with no or mild PLE was 42 (SD 21) compared
with 55 (SD 24) in the patients with moderate to severe
PLE (p=0.03).
As shown in figure 3, self-reported NYHA-class and
MLHFQ-score correlated well at baseline (r=0.63,
p<0.001). MLHFQ-score was higher with more severe
symptoms (NYHA-class 1 to 4) with p=0.001 for trend.
A MLHFQ-score >40 was observed for seven of nine
patients with severe PLE amounts and for 15 of 19
patients with moderate to severe PLE (sensitivity 78%
and specificity 49%). The corresponding positive and
negative predictive values were 40% and 84% for the
detection of moderate to severe PLE.
In total, the mean reduction of PLE during follow-up
was 0.8 cm (SD 2.1 cm; range from −9.7 to +0.7 cm). For
obvious reasons, the reduction of PLE was greatest
among those with moderate to severe amount (−2.6 cm,
SD 3.5, range from −9.7 to +0.7 cm) compared with
those with only mild or no PLE (−0.07 cm, SD 0.2,
range from −1.0 to 0 cm). During follow-up, the patients
improved their MLHFQ-score by an average of 17 points
(SD 27, range from −79 to +42). A total of 17 patients
(61%) had a clinically significant improvement in
MLHFQ-score of >5 points reduction and 25 (86%)
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patients reported an improvement in NYHA-class. There
was no difference in the proportion of patients who
experienced clinically meaningful improvement in
MLHFQ-score by dichotomised PLE groups (p=0.2).
The improvement in MLHFQ-score correlated with
improvement of NYHA-class (r=0.44, p=0.02). We
observed a linear improvement in the MLHFQ-score
(3.2 points, 95% CI 1.2 to 5.1) with each cm reduction
in PLE. This improvement in MLHFQ was not explained
by any of the adjustments for age, sex, β-blockers,
bumetanide-equivalent, ACEI/ARB, change in weight or
change in blood pressure over time (see table 2).
Figure 4 shows the linear two-way association of
MLHFQ-score with the reduction of PLE over time. The
odds for reduction in NYHA-class per cm reduction in
PLE was 1.06 (95% CI 1.04 to 1.08, p<0.001) and none
of the seven adjustments models explained the associ-
ation (data not shown).
Figure 2 Shows the MLHFQ-score by amount of PLE in four
categories at baseline. MLHFQ-score, Minnesota Living with
Heart Failure Questionnaire score; PLE, pleural effusion.
Figure 3 Shows MLHFQ-score by self-reported NYHA-class
at baseline. MLHFQ-score, Minnesota Living with Heart
Failure Questionnaire score; NYHA-class, New York Heart
Association functional classification.
Table 1 Baseline characteristics by the amount of pleural effusion
No or mild pleural
effusion (n=43)
Moderate to severe pleural
effusion (N=19) p between groups
Variables mean ±SD (range) mean ±SD (range)
Age, years 74±12 (35–91) 75±11 (49–92) 0.69
Systolic blood pressure (mm Hg) 125±24 (85–171) 115±18 (80–150) 0.12
Diastolic blood pressure (mm Hg) 73±14 (50–107) 68±13 (50–99) 0.23
Heart rate (bpm) 75±18 (51–121) 88±26 (56–140) 0.02
NT-proBNP (ng/L) 3252±2907 (90–9999) 5130±3320 (93–9999) 0.04
e-GFR (ml/min) 51±20 (16–88) 53±23 (26–99) 0.73
Bumetanide-equivalent (mg) 2.2±2.5 (0–13) 2.1±1.5 (0–6) 0.80
Weight 85±19 (56–141) 75±18 (49–120) 0.05
MLHFQ-score 42±21 (0–92) 55±24 (11–91) 0.03
n (%) n (%)
Women 20 (47) 10 (53) 0.66
Sinus rhythm (yes) 21 (49) 4 (21) 0.04
Medication
Beta-blockers (yes) 35 (81) 14 (74) 0.49
ACEI or ARB (yes) 26 (61) 11 (58) 0.85
Patient-reported NYHA-class 0.23
NYHA-class 1 3 (7) 1 (5)
NYHA-class 2 24 (56) 6 (32)
NYHA-class 3 9 (21) 5 (26)
NYHA-class 4 7 (16) 7 (37)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; eGFR, estimated glomerulus filtration rate; MLHFQ-score,
Minnesota Living with Heart Failure Questionnaire score; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA-class, New York Heart
Association functional classification.
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DISCUSSION
Our study of outpatients with HF demonstrates that
patient-reported QoL, by MLHFQ, is a sensitive tool for
identifying patients with HF with severe amount of PLE.
Furthermore, we found an improvement in
MLHFQ-score and NYHA-class associated with reduction
of PLE. A reduction of 1 cm of PLE corresponded to a
reduction of 3.2 points in MLHFQ-score and 1.06
higher odds of improvement in functional class. In the
models used, it seems that the change in PLE over time
explains the improvement in MLHFQ-score and
NYHA-class. Thus, paying attention to and treating PLE
in follow-up of patients with HF may be important also
with respect to improved symptoms and QoL.
To the best of our knowledge, no study has assessed
the sensitivity of MLHFQ to detect PLE among
outpatients with HF. We find that the MLHFQ is a sensi-
tive tool for detecting severe PLE in HF follow-up, and
that a MLHFQ-score >40 should warrant further exam-
ination to search for PLE. The MLHFQ-score cut-off at
40 ensured that the impact on QoL for most of the
patients with moderate–severe PLE was observed.
However, half of the patients without PLE had
MLHFQ-score >40 and treatment of PLE based solely
on QoL is not advisable. However, as early detection of
PLE is crucial for optimal follow-up of patients with HF,
a moderate or worsened QoL should drive further diag-
nostic approach, and thereafter treatment. The
MLHFQ-score is an easy and cheap method to raise the
suspicion of PLE in patients with HF, and thus, should
be routinely applied.
Our study is also the first to describe the associations
of reduced amount of PLE with improved self-reported
MLHFQ-score and NYHA-class among patients with HF.
The relation between HF symptoms and patient-
reported outcomes is an area outlined in need of future
research.19 The improvement in MLHFQ-score and
NYHA-class were intercorrelated and in line with a previ-
ous study that showed improvement of MLHFQ-score
during follow-up in a multidisciplinary HF
programme.20
Point-of-care ultrasound of the pleural cavities is a sen-
sitive and specific test for detection of PLE,1 21 and is
previously shown to be superior to chest X-ray for diag-
nostics of PLE.22 The current study indicates that caring
for improvement of patient-reported outcomes is an
additional reason for systematic use of ultrasound to
assess PLE in patients with HF,21 as excessive volume
status could be an explanation for the poor QoL.
However, if the availability of ultrasound is limited, a
MLHFQ-score >40 identifies ∼80% of those with moder-
ate to severe PLE and these should be referred to
ultrasound.
A determinant for the improvement in MLHFQ-score
in an earlier study was found to be correlated with
increased systolic blood pressure.20 In our study, adjust-
ment for change in systolic blood pressure did not alter
the improvement in MLHFQ-score associated with PLE
reduction. However, the blood pressure was considered
before titrating HF medication in order to prevent
hypotension.
Respiratory symptoms have been reported to reduce
QoL in patients with cancer23 and PLE is associated with
respiratory symptoms in patients with HF.2 4 The
observed improvement in QoL and NYHA-class may be
influenced by the expected improvement in respiratory
symptoms through other mechanisms causing dyspnoea
in HF and not only by the PLE reduction per se.
However, in palliative care, intermittent pleural drainage
is often associated with superior palliation, improvement
of QoL and decreased morbidity compared with no
treatment of the PLE,9 24 and we observed a reduction
of PLE to be copresent with improvement in symptoms
following targeted treatment.
Table 2 Change in patient-reported Minnesota Living
with Heart Failure Questionnaire (MLHFQ)-score by




Model 1 Age 3.1 (1.1 to 5.0)
Model 2 Age + sex 3.1 (1.0 to 5.2)
Model 3 Model 1+ beta-blockers 3.2 (1.3 to 5.2)
Model 4 Model 1+ bumetanide
equivalent (in mg)
3.1 (1.1 to 5.0)
Model 5 Model 1+ weight
(change over time)
3.2 (0.8 to 5.5)
Model 6 Model 1+ACEI or ARB 3.1 (0.9 to 5.2)
Model 7 Model 1+ systolic BP
(change over time)
3.0 (0.6 to 5.5)
ß indicates the decrease in MLHFQ-score per cm decrease of
PLE (95% CI) over time.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BP, blood pressure (mm Hg).
Figure 4 Shows change in MLHFQ-score by change in PLE
graphed by linear regression approach. MLHFQ-score,
Minnesota Living with Heart Failure Questionnaire score; PLE,
pleural effusion.
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Nevertheless, the study also has limitations. The study
was conducted at a single HF outpatient clinic and the
sample size was small with limited number of patients
with severe HF and large PLE. However, the presented
population is previously shown to be comparable with
studies from other HF clinics with regard to HF severity,
age, sex, NYHA-class and comorbidity and thus, it is
plausible that our results are generalisable to other HF
clinics.11 Assessment of HF symptoms is difficult because
of the subjective nature of the symptoms. Incorporation
of patient-reported outcome measures in clinical prac-
tice may be important to improve management and care
for patients with HF.13 25 26
Poor patient-reported MLHFQ-score and
NYHA-classification are previously shown to be a strong
predictor for early death in patients with HF.5 20 25 27
Improvement of MLHFQ-score during follow-up of HF
is previously shown to predict event-free survival.20 28 29
The low number of participants do not allow for sur-
vival analyses. However, self-report to detect PLE is
useful as patients may prefer a better QoL over pro-
longed life.30
As patient-reported QoL is increasingly emphasised in
treatment strategies, further studies should be per-
formed in order to evaluate the need for more system-
atic identification and earlier intervention aiming to
reduce PLE in follow-up of patients with HF.
CONCLUSIONS
The MLHFQ-score seems sensitive to detect severe PLE.
Patient-reported outcome measures like the
MLHFQ-score and NYHA-class were associated with the
amount of PLE. Further, the long-term improvement in
MLHFQ-score and NYHA-class were associated with
reduced amount of PLE. Thus, reducing PLE may be
important to improve the QoL in patients with HF.
Routinely including patient-reported outcomes in
follow-up of outpatients with HF may identify those at
highest risk of having symptomatic amount of PLE and
may allow for further improvement in the care for these
patients. Further studies are needed to draw definitive
conclusions regarding the interrelationship between
PLE, QoL assessment and outcomes.
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